Paper41009897
Assessment of Factors Contributing to Multidrug Resistance in Urinary Tract Infections: Focus on Carbapenem Resistance.
Bandac CA and 9 others. Antibiotics (Basel), 2025. Cited by 5 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Assessment of Factors Contributing to Multidrug Resistance in Urinary Tract Infections: Focus on Carbapenem Resistance. Papers, record 41009897. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41009897
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Assessment of Factors Contributing to Multidrug Resistance in Urinary Tract Infections: Focus on Carbapenem Resistance.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References48
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 29,115,369 | Useful independent factors for distinguish infection and colonization in patients with urinary carbapenemase-producing Enterobacteriaceae isolation. | Rev Esp Quimioter | 2017 | https://conductscience.org/library/papers/29115369 | PubMed |
| 2 | 37,951,832 | The risk factors, antimicrobial resistance patterns, and outcomes associated with extended-spectrum β-lactamases-Producing pathogens in pediatric urinary tract infection. | Pediatr Neonatol | 2024 | https://conductscience.org/library/papers/37951832 | PubMed |
| 3 | 37,370,292 | Multidrug-Resistant (MDR) Urinary Tract Infections Associated with Gut Microbiota in CoV and Non-CoV Patients in a Urological Clinic during the Pandemic: A Single Center Experience. | Antibiotics (Basel) | 2023 | https://conductscience.org/library/papers/37370292 | PubMed |
| 4 | 25,461,239 | Efficacy of empirical therapy with non-carbapenems for urinary tract infections with extended-spectrum beta-lactamase-producing Enterobacteriaceae. | Int J Infect Dis | 2014 | https://conductscience.org/library/papers/25461239 | PubMed |
| 5 | 39,504,496 | Resistance profiles of carbapenemase-producing Enterobacterales in a large centre in England: are we already losing cefiderocol? | J Antimicrob Chemother | 2025 | https://conductscience.org/library/papers/39504496 | PubMed |
| 6 | 21,292,654 | International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. | Clin Infect Dis | 2011 | https://conductscience.org/library/papers/21292654 | PubMed |
| 7 | 37,176,622 | A 2-Year Audit on Antibiotic Resistance Patterns from a Urology Department in Greece. | J Clin Med | 2023 | https://conductscience.org/library/papers/37176622 | PubMed |
| 8 | 36,767,330 | Identification and Preliminary Hierarchisation of Selected Risk Factors for Carbapenemase-Producing Enterobacteriaceae (CPE) Colonisation: A Prospective Study. | Int J Environ Res Public Health | 2023 | https://conductscience.org/library/papers/36767330 | PubMed |
| 9 | 37,086,890 | Epidemiology and risk factors for carbapenemase-producing Enterobacteriaceae carriage in the hospital: A population-based nested case-control study. | J Glob Antimicrob Resist | 2023 | https://conductscience.org/library/papers/37086890 | PubMed |
| 10 | 34,055,063 | Antibiotic resistance patterns of urinary tract pathogens in children from Central Romania. | Exp Ther Med | 2021 | https://conductscience.org/library/papers/34055063 | PubMed |
| 11 | 32,752,222 | Spectrum and Antibiotic Resistance of Uropathogens in Romanian Females. | Antibiotics (Basel) | 2020 | https://conductscience.org/library/papers/32752222 | PubMed |
| 12 | 38,817,448 | Characterizing carbapenemase-producing Escherichia coli isolates from Spain: high genetic heterogeneity and wide geographical spread. | Front Cell Infect Microbiol | 2024 | https://conductscience.org/library/papers/38817448 | PubMed |
| 13 | 38,675,369 | Pre- and Post-COVID-19 Antimicrobial Resistance Pattern of Pathogens in an Intensive Care Unit. | Pharmaceuticals (Basel) | 2024 | https://conductscience.org/library/papers/38675369 | PubMed |
| 14 | 40,059,962 | Carbapenem de-escalation as an antimicrobial stewardship strategy: a narrative review. | JAC Antimicrob Resist | 2025 | https://conductscience.org/library/papers/40059962 | PubMed |
| 15 | 28,375,512 | The Epidemiology of Carbapenem-Resistant Enterobacteriaceae: The Impact and Evolution of a Global Menace. | J Infect Dis | 2017 | https://conductscience.org/library/papers/28375512 | PubMed |
| 16 | 31,865,666 | Carbapenem-resistant Klebsiella pneumonia infection outbreak in a tertiary urology clinic: analysis of influencing factors with a controlled trial | Turk J Med Sci | 2020 | https://conductscience.org/library/papers/31865666 | PubMed |
| 17 | 39,597,809 | Multidrug-Resistant Urinary Tract Infections in Pregnant Patients and Their Association with Adverse Pregnancy Outcomes-A Retrospective Study. | J Clin Med | 2024 | https://conductscience.org/library/papers/39597809 | PubMed |
| 18 | 34,447,478 | Insights into multidrug-resistant K. pneumoniae urinary tract infections: From susceptibility to mortality. | Exp Ther Med | 2021 | https://conductscience.org/library/papers/34447478 | PubMed |
| 19 | 39,693,165 | Detection and characterization of carbapenemase-producing Enterobacteriaceae in cancer patients: first Sri Lankan report of blaVIM in Enterobacteriaceae. | J Infect Dev Ctries | 2024 | https://conductscience.org/library/papers/39693165 | PubMed |
| 20 | 25,908,966 | Multidrug resistant and carbapenemase producing Enterobacteriaceae among patients with urinary tract infection at referral Hospital, Northwest Ethiopia. | Antimicrob Resist Infect Control | 2015 | https://conductscience.org/library/papers/25908966 | PubMed |
Cited by6
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 5 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,792,016 | Predictors of In-Hospital Mortality Among Hospitalized Colistin-Treated Patients at a Tertiary Urology-Nephrology Referral Center. | Antibiotics (Basel) | 2026 | https://conductscience.org/library/papers/42792016 | PubMed |
| 42,650,694 | Nitrofurantoin Susceptibility and the Landscape of Multidrug-Resistant Gram-Negative Uropathogens in Kidney Transplant Recipients During the First Post-Transplant Year. | Antibiotics (Basel) | 2026 | https://conductscience.org/library/papers/42650694 | PubMed |
| 42,513,997 | The Resistance Landscape of Uropathogens in a Romanian Tertiary Center: A 13-Month Single-Center Study with Focus on Klebsiella and Urease-Positive Organisms. | Microorganisms | 2026 | https://conductscience.org/library/papers/42513997 | PubMed |
| 42,353,734 | Efficacy and Safety of Meropenem in Pregnant Women with Upper Urinary Tract Infections: A Retrospective Cohort Study in Romania. | Antibiotics (Basel) | 2026 | https://conductscience.org/library/papers/42353734 | PubMed |
| 41,892,432 | Novel Insights into Carbapenem Resistance: Mechanisms, Diagnostics, and Future Directions. | Antibiotics (Basel) | 2026 | https://conductscience.org/library/papers/41892432 | PubMed |
| 41,463,745 | Changes in Antimicrobial Resistance in Pediatric Urinary Pathogens Before, During, and After the COVID-19 Pandemic. | Antibiotics (Basel) | 2025 | https://conductscience.org/library/papers/41463745 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41009897
GET https://conductscience.org/api/papers/v1/41009897/references?page=2